Molecular Tumor Board: 33 year-old female with locally advanced ER/PR-negative, HER2-positive breast cancer

Recognizing and mitigating cancer treatment toxicities is an essential piece of a survivorship plan after curaing cancer. Our latest molecular tumor board discusses an important intersection of cardiology and oncology in breast cancer through a case of a 33-year-old female with locally advanced ER/PR-negative, HER2-positive breast cancer. We reviewed side effect profiles of anthracyclines and anti-HER2 monoclonal antibodies along with recent updated recommendations from European Society of Cardiology on cardiovascular surveillance and risk assessment in long-term follow up after discontinuation of cancer treatment.